

Drug resistance interpretation: PR		HIVDB 9.5.1 (2023-11-05)
PI Major Mutations:	None	
PI Accessory Mutations:	None	
PR Other Mutations:	I13V <small>100% seen=2,000</small> • G17E <small>94% seen=2,902</small> • K20R <small>99% seen=2,875</small> • E35N <small>99% seen=3,875</small> • M36I <small>99% seen=3,875</small> • R41K <small>99% seen=3,802</small> • K45R <small>99% seen=3,875</small> • R57K <small>99% seen=3,802</small> • L63S <small>99% seen=3,344</small> • H69K <small>99% seen=3,203</small> • L89M <small>100% seen=5,000</small>	
Protease Inhibitors		
atazanavir/r (ATV/r)	Susceptible	
darunavir/r (DRV/r)	Susceptible	
fosamprenavir/r (FPV/r)	Susceptible	
indinavir/r (IDV/r)	Susceptible	
lopinavir/r (LPV/r)	Susceptible	
nelfinavir (NFV)	Susceptible	
saquinavir/r (SQV/r)	Susceptible	
tipranavir/r (TPV/r)	Susceptible	
PR comments		
Other		
<ul style="list-style-type: none"><li>K20R is a highly polymorphic PI-selected accessory mutation that increases replication fitness in viruses with PI-resistance mutations.</li></ul>		

Mutation scoring: PR	HIVDB 9.5.1 (2023-11-05)
----------------------	--------------------------

No drug resistance mutations were found for PI.

Drug resistance interpretation: RT	HIVDB 9.5.1 (2023-11-05)
------------------------------------	--------------------------

NRTI Mutations:	None	
NNRTI Mutations:	None	
RT Other Mutations:	E6K <small>100% seen=2,000</small> • V35T <small>100% seen=2,000</small> • T39L <small>95% seen=3,990</small> • E40D <small>92% seen=3,363</small> • V60I <small>95% seen=3,908</small> • K122E <small>100% seen=1,000</small> • D123S <small>95% seen=1,008</small> • I135T <small>99% seen=1,262</small> • I142V <small>95% seen=1,290</small> • S162HY <small>96-77% seen=1,526</small> • K173S <small>100% seen=1,802</small> • D177E <small>100% seen=1,875</small> • V179I <small>100% seen=1,883</small> • Q207A <small>100% seen=1,428</small> • R211S <small>100% seen=1,501</small> • V245I <small>95% seen=580</small>	
<div><div>Nucleoside Reverse Transcriptase Inhibitors</div><div><div>abacavir (ABC)</div><div>Susceptible</div></div><div><div>zidovudine (AZT)</div><div>Susceptible</div></div><div><div>stavudine (D4T)</div><div>Susceptible</div></div><div><div>didanosine (DDI)</div><div>Susceptible</div></div><div><div>emtricitabine (FTC)</div><div>Susceptible</div></div><div><div>lamivudine (3TC)</div><div>Susceptible</div></div><div><div>tenofovir (TDF)</div><div>Susceptible</div></div></div> <div><div>Non-nucleoside Reverse Transcriptase Inhibitors</div><div><div>doravirine (DOR)</div><div>Susceptible</div></div><div><div>efavirenz (EFV)</div><div>Susceptible</div></div><div><div>etravirine (ETR)</div><div>Susceptible</div></div><div><div>nevirapine (NVP)</div><div>Susceptible</div></div><div><div>rilpivirine (RPV)</div><div>Susceptible</div></div></div>		

RT comments	
Other	
• V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility.	

Mutation scoring: RT	HIVDB 9.5.1 (2023-11-05)
----------------------	--------------------------

No drug resistance mutations were found for NRTI.

No drug resistance mutations were found for NNRTI.